<DOC>
	<DOCNO>NCT02851914</DOCNO>
	<brief_summary>Depression see 9-11 % ALS patient adequate proper treatment need . In study , ALS patient screen depression use self-reported multiple choice questionnaire . Patients fulfill criterion depression base screen tool evaluate psychiatrist inclusion study . The investigator also measure quality life functional status simple questionnaire . The patient allocate two treatment group receive either TCA SSRI 12 week . Patients evaluate every 4 week phone call make visit need assess efficacy side effect . If patient report suicidal thought phone call clinic visit , he/she immediately send ER appropriate management . The investigator repeat questionnaire clinic visit , use data analysis look improvement compare two medication class use study . This data may use later large study help make standard recommendation treat depression ALS patient .</brief_summary>
	<brief_title>SSRIs vs. TCAs Depression ALS Patients</brief_title>
	<detailed_description>This study 12-week , open-label , non-randomized , pilot clinical intervention trial . This investigator initiate study.This trial do St Louis University ALS clinic . ALS patient screen depression use Beck depression inventory ( BDI-II ) scale . A mental healthcare provider evaluate patient score 19 , inclusion study . Quality Life ( QOL ) assessment questionnaire ( McGill ) ALS functional rating scale ( ALS-FRS ) measurement do baseline . Then patient allocate two treatment group receive either TCA SSRI medication 12 week base clinical judgment ( non-randomized ) . Patients require clinical encounter every 4 week telephone encounter visit assess effectiveness medication tolerability side effect . If patient endorses active suicidal ideation assessment , he/she immediately send ER appropriate management . At 4 , 8 12-week clinic visit , repeat BDI , QOL ALS-FRS measurement do patient group use data analysis .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Antidepressive Agents , Tricyclic</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Documented diagnosis definite probable ALS Informed write consent enrollment study Gender : male female Age : 2580 year BDI score 19 Depression diagnosis mental health provider History psychotic disorder , premorbid bipolar depression ALSFRS score &lt; 26 Cognitive impairment Currently SSRIs TCAs . However reason treatment , enrol study washout period 30 day . Currently antidepressants monoamine oxidase inhibitor ( MAOIs ) , selective norepinephrine reuptake inhibitor ( SNRIs ) etc .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>